Alkion BioPharma was founded in 2011 to revolutionize the secondary metabolims production for cancer therapies.
Imperial Innovations, a team of Imperial College researchers & business professionals joined together to develop the technologies able to transform non-GMO plants into a natural biorefinery.
Quickly the technological platform received strong interests from the cosmetics community and the company signed research contracts to develop new disruptive cosmetics ingredients.
Four years after the company was founded, boasting a strong commercial pipeline, Alkion BioPharma was acquired by Evonik Industries AG for cosmetics & food supplements applications.
The same founding team created Alkion BioInnovations in March 2017 in order to develop disruptive pharmaceutical & agri-food solutions. The company owns the exclusive rights on these applications.
In 2018, the team was granted the first historical R&D license from French authorities for their work on Cannabis and major & minor cannabinoids.